Results

1–10 of 127 results for Age-Related Macular Degeneration

Early Signs of Atrophy in AMD, Nascent GA (nGA) and the Difference Between nGA and iRORA
Robyn H Guymer, MB BS PhD FRANZCO
Updates from the Field
2023
Unsupervised Deep Learning for Grading Age-Related Macular Degeneration Using Retinal Fundus Images
Neesurg S Mehta, MD
On Demand Cases, Courses, and Papers
2021
Dual Anti-platelet Therapy Decelerates the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Yodpong Chantarasorn, MD
On Demand Cases, Courses, and Papers
2021
Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration (nAMD)
Nathan C. Steinle, MD
On Demand Cases, Courses, and Papers
2021
The Role of Subretinal Surgery in the Treatment of Resistant Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Nabil M. Jabbour, MD, FACS
On Demand Cases, Courses, and Papers
2021
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021